Organic revenue for the quarter ended December 31, 2024, increased 9% compared to the prior year. This growth was primarily driven by broad based performance of our Diagnostics and Spatial Biology portfolio as well as improving biopharma end market conditions.

A key component of the Company's strategy is to augment internal growth at existing businesses with complementary acquisitions. The Company did not make any acquisitions in the first half of fiscal 2025.

In July 2024, the Company paid $15 million to enter into an investment in Spear Bio. This investment is accounted for under the cost-method as we own less than 20% of the outstanding stock and we concluded that we do not have significant influence.

In the first quarter of fiscal 2025, the Company announced enterprise-wide restructuring focused on recovering operating margins and optimizing our manufacturing footprint. The Company is expecting to incur costs related to these actions through fiscal 2026.

Capital expenditures for the remainder of fiscal 2025 are expected to be approximately $20 million. Capital expenditures are expected to be financed through currently available funds and cash generated from operating activities. Expected additions in fiscal 2025 are related to increasing capacity to meet expected sales growth across the Company.

Based on management's evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2024, the company's disclosure controls and procedures were effective.

During the quarter and six months ended December 31, 2024, there have been no material changes from the risk factors found in Part I, Item 1A, 'Risk Factors,' of the Company's Annual Report on Form 10-K for the year ended June 30, 2024.

As of February 6, 2025, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

Organic growth for the segment for the quarter ended December 31, 2024 was 12% from the prior year, with foreign currency exchange not having a material impact. Organic revenue growth for the six months ended December 31, 2024 was 13% compared to the prior year, with foreign currency exchange not having a material impact.

Selling, general and administrative expenses increased 5% to $121.5 million and increased 9% to $240.6 million for the quarter and six months ended December 31, 2024, respectively, from the same prior year periods. The increase in expense for the quarter and six months ended December 31, 2024 was primarily due to restructuring and restructuring-related charges.

There were $75.6 million and $80.0 million of share repurchases during the six months ended December 31, 2024 and December 31, 2023, respectively, included as a cash outflow within financing activities.

During the six months ended December 31, 2024 and December 31, 2023, the Company paid cash dividends of $25.4 million and $25.2 million, respectively, to all common shareholders.

Excluding the impact of discrete items, the Company expects the consolidated income tax rate for the remainder of fiscal 2025 to range from 23% to 27%.